Your new post is loading...
Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, the world's largest clinical cancer research meeting.
Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated cancer center in Florida, is presenting new data from dozens of clinical research studies at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, the largest clinical cancer research meeting in the world. Moffitt investigators will lead 25 abstract presentations, five educational sessions, two cancer panels and two clinical science symposia. The virtual meeting will take place June 4-8, 2021. Among those presenting will be Dr. Bijal Shah, who will discuss the results of the Phase 2 ZUMA-3 trial evaluating CAR T-cell therapy for adults with acute lymphoblastic leukemia, a difficult-to-treat malignancy in this patient population. Also on hand will be Dr. Frederick Locke, who will present data from the ALPHA2 trial evaluating ALLO-501, an allogeneic CAR T-cell therapy product, in combination with ALLO-647, a monoclonal antibody that depletes lymphocytes in the body to help prepare the patient to receive new immune cells, in patients with large B-cell lymphoma.